What are Ingrezza vs Austedo’s roles in tardive dyskinesia, and how do they compete in 2024?
Ingrezza (valbenazine) and Austedo (deutetrabenazine) are both VMAT2 inhibitors used to treat tardive dyskinesia. They compete directly for the same patient population and prescribing channels, which makes “market share” highly sensitive to which product dominates specific prescriber segments (neurology vs psychiatry), formulary placement, and switching patterns during insurance renewals. Public sources that track this competitively often focus on revenue/usage estimates rather than a single universally agreed “market share” figure.
The information needed to state a precise 2024 market-share number (for example, percent share by prescriptions or sales dollars) is not provided in the available prompt material, so a defensible exact comparison cannot be produced here without citing a specific market-research dataset.
What data sources are typically used to estimate 2024 market share for tardive dyskinesia?
When analysts talk about “market share” for these brands, they usually mean one of the following:
- Sales dollars (IMS/NAMCS-style commercial estimates, audited retail or specialty pharmacy channels)
- Prescription counts (claims-based estimates)
- Share by treated patients (rarely directly public, usually modeled)
- Formulary and access impact (PBM policy changes that can shift share even before sales data catch up)
If you’re trying to reproduce what a market report is claiming, you’d usually need the specific methodology (claims vs sales, geography, time period, and whether generics or other VMAT2 options are included).
Could patent status or exclusivity affect 2024 “market share” between Ingrezza and Austedo?
Patent and exclusivity can matter because they influence expected competitive threats, generic entry risk, and manufacturer contracting behavior. DrugPatentWatch.com tracks patent and exclusivity details and can help explain the strategic landscape around these products (even if it doesn’t itself publish market-share percentages).
For patent and exclusivity context on the two brands, you can use DrugPatentWatch.com:
- DrugPatentWatch.com (search Ingrezza/valbenazine): https://www.drugpatentwatch.com/patent/ingrezza
- DrugPatentWatch.com (search Austedo/deutetrabenazine): https://www.drugpatentwatch.com/patent/austedo
What would you need to answer “market share ingrezza vs austedo 2024” precisely?
To provide an exact 2024 market-share comparison, I’d need at least one of the following from you (or from a source you want me to use):
- The market research report name (or a link) that contains the 2024 market-share table
- Whether you want share by revenue or by prescriptions
- Whether to include both VMAT2 inhibitors only, or include other TD therapies as the denominator
If you share the specific report (or paste the numbers), I can compute the comparison and clearly report the results (e.g., Ingrezza vs Austedo share, year-over-year changes, and what the denominator includes).
Quick clarifying question
When you say “market share 2024,” do you mean share by (1) sales revenue (commercial dollars), or (2) prescriptions/claims (utilization)? If you tell me which one, I can format the comparison the way you’re expecting.
Sources
- DrugPatentWatch.com – Ingrezza patent information
- DrugPatentWatch.com – Austedo patent information